

Supplemental Table 1: Prevalence of psychiatric symptoms after COVID-19

	Sample size	Follow up	Questionnaire	Symptom frequency
Insomnia symptoms				
Poyraz et al [1]	284	14 days	PSQI	38.8%
Mazza et al [2]	402	1 month	MOS	40.0%
Morin et al [3]	177	4 months	ISI	53.6%
Garrigues et al [4]	120	3 months	Self reported	30.8%
Frontera et al [5]	281	6 months	Neuro-QoL	36.0%
Anxiety symptoms				
Liu et al [6]	675	1 month	GAD -7	10.4 %
Poyraz et al, [1]	284	14 days	HADS	18.4 %
Tomasoni et al [7]	105	1 to 3 months	HADS	29.0%
Mazza et al, [2]	402	1 month	STAI	42.0%
Méndez et al [8]	179	2 months	GAD -7	29.6%
de Graaf et al [9]	81	1.5 months	GAD -7	5.0%
Mei et al [10]	4328	4 months	GAD -7	12.2%
Mazza et al [11]	226	3 months	STAI	30.0%
Taylor et al [12]	675	3 months	GAD -7	19.8%
Morin et al, [3]	177	4 months	HADS	31.4%
Todt et al [13]	251	3 months	PHQ-4	32.2%
Frontera et al [5]	281	6 months	Neuro-QoL	46.0%
Fortini et al [14]	69	3-6 months	self reported	22.0%
Van den Borst [15]	121	2.5 months	HADS	10.0%
Wang et al [16]	215	2-4 months	GAD-7	24.2%
Carenzo et al [17]	47	6 months	EQ-5D-5L	21.2%
Hall et al [18]	200	1 month	GAD-7	11.0%
Raman et al [19]	58	2-3 months	GAD-7	14.0%
Schandl et al [20]	75	5 months	HADS	33.0%
Huang et al [21]	1733	6 months	EQ-5D-5L	23.0%
Depressive symptoms				
Liu et al [6]	675	1 month	PHQ-9	19.0 %
Poyraz et al, [1]	284	14 days	HADS	18.8 %
Tomasoni et al [7]	105	1 to 3 months	HADS	11.0%
Mazza et al, [2]	402	1 month	BDI-13	31.0%
Méndez et al [8]	179	2 months	PHQ-2	26.8%
de Graaf et al [9]	81	1.5 months	PHQ-9	17.0%
Mandal et al [22]	384	2 months	PHQ-2	14.6%
Mei et al [10]	4328	4 months	GAD -7	12.2%
Mazza et al [11]	226	3 months	BDI-13	9.0%
Taylor et al [12]	675	3 months	PHQ-2	24.1%
Morin et al, [3]	177	4 months	HADS	21.7%
Todt et al [13]	251	3 months	PHQ-4	32.2%
Fortini et al [14]	69	3-6 months	self reported	22.0%
Frontera et al [5]	281	6 months	Neuro-QoL	25.0%
Naidu et al [23]	946	2 months	PHQ-2	13.8%

Wang et al [16]	215	2-4 months	CES-D	41.6%
Carenzo et al [17]	47	6 months	EQ-5D-5L	21.2%
Hall et al [18]	200	1 month	PHQ-9	16.0%
Raman et al [19]	58	2-3 months	PHQ-9	19.3%
Van den Borst et al [15]	121	2.5 months	HADS	12.0%
Schandl et al [20]	75	5 months	HADS	36.0%
Huang et al [21]	1733	6 months	EQ-5D-5L	23.0%
Post-traumatic stress symptoms				
Liu et al [6]	675	1 month	PCL-5	12.4 %
Poyraz et al, [1]	284	14 days	IES-R	25.4%
Mazza et al, [2]	402	1 month	IES-R	28.0%
Méndez et al [8]	179	2 months	DTS-17	25.1%
de Graaf et al [9]	81	1.5 months	PCL-5	10.0%
Mazza et al [11]	226	3 months	IES-R	22.0%
Taylor et al [12]	675	3 months	TSQ	15.4%
Morin et al, [3]	177	4 months	PCL-5	14.2%
Halpin et al [24]	100	1 to 2 months	Self reported	31.0%
Bellan et al [25]	232	4 months	IES-R	42.9%
Van den Borst et al [15]	121	2.5 months	IES-R	10.0%
Naidu et al [23]	946	2 months	PHQ-2	10.5%
Wang et al [16]	215	2-4 months	PTSD-5	34.1%
Carenzo et al [17]	47	6 months	IES-R	57.4%
Yuan et al [26]	134	3 to 6 months	PCL-5	18.8%
Schandl et al [20]	75	5 months	PTSS	35.0%
Frontera et al [5]	281	6 months	Neuro-QoL	36.0%

BDI-13 : Beck Depression Inventory 13 items, CEZS-D Center for Epidemiologic Studies Depression Scale, DTS-17 : Davidson trauma Scale 17 items, EQ-5D-5L : Euro-QoL-5 dimensions-5 levels, GAD-7 : Generalized Anxiety Disorder 7 items, HADS : Hospital Anxiety and Depression Scale, IESR : Impact of Events Scale-Revised, ISI: Insomnia Severity Index, Neuro-QoL : Neurological- Quality of life, MOS: Medical Outcomes Study Sleep Scale PCL-5 : PTSD CheckList for DSM-5, PHQ : Patient's Health Questionnaire, Pittsburgh Sleep Quality Index: PSQI, PTSD-5 PTSD screen for DSM-5, PTSS : Post Traumatic Symptoms Scale, STAI : State Trait Anxiety Inventory, TSQ : Trauma Screening Questionnaire, WEMS :Warwick-Edinburgh Mental Wellbeing Scales

REFERENCES

1. Poyraz BÇ, Poyraz CA, Olgun Y, Gürel Ö, Alkan S, Özdemir YE, Balkan İİ, Karaali R. Psychiatric morbidity and protracted symptoms after COVID-19. *Psychiatry Res* 2021; 295: 113604.
2. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P, COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain Behav Immun* 2020; 89: 594–600.
3. Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, Harrois A, Gasnier M, Lecoq A-L, Meyrignac O, Noel N, Baudry E, Bellin M-F, Beurnier A, Choucha W, Corruble E, Dortet L, Hardy-Leger I, Radiguer F, Sportouch S, Verny C, Wyplosz B, Zaidan M, Becquemont L, Montani D, Monnet X. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA* 2021; .
4. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, Doucet L, Berkani S, Oliosi E, Mallart E, Corre F, Zarrouk V, Moyer J-D, Galy A, Honsel V, Fantin B, Nguyen Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect* 2020; 81: e4–e6.
5. Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, Fang T, Andino A, Snyder T, Madhavan M, Gratch D, Fuchs B, Dessy A, Canizares M, Jauregui R, Thomas B, Bauman K, Olivera A, Bhagat D, Sonson M, Park G, Stainman R, Sunwoo B, Talmasov D, Tamimi M, Zhu Y, Rosenthal J, Dygert L, Ristic M, Ishii H, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. *J Neurol Sci* 2021; 426: 117486.
6. Liu D, Baumeister RF, Veilleux JC, Chen C, Liu W, Yue Y, Zhang S. Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China. *Psychiatry Res* 2020; 292: 113297.
7. Tomasoni D, Bai F, Castoldi R, Barbanotti D, Falcinella C, Mulè G, Mondatore D, Tavelli A, Vegni E, Marchetti G, d'Arminio Monforte A. Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. *J Med Virol* 2021; 93: 1175–1179.
8. Méndez R, Balanzá-Martínez V, Luperdi SC, Estrada I, Latorre A, González-Jiménez P, Feced L, Bouzas L, Yépez K, Ferrando A, Hervás D, Zaldívar E, Reyes S, Berk M, Menéndez R. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. *J Intern Med* 2021; .
9. de Graaf MA, Antoni ML, Ter Kuile MM, Arbous MS, Duiniveld AJF, Feltkamp MCW, Groeneveld GH, Hinnen SCH, Janssen VR, Lijfering WM, Omara S, Postmus PE, Ramai SRS, Rius-Ottenheim N, Schalij MJ, Schiemanck SK, Smid L, Stöger JL, Visser LG, de Vries JJC, Wijngaarden MA, Geelhoed JJM, Roukens AHE. Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach. *EClinicalMedicine* 2021; 32: 100731.
10. Mei Q, Wang F, Bryant A, Wei L, Yuan X, Li J. Mental health problems among COVID-19 survivors in Wuhan, China. *World Psychiatry* 2021; 20: 139–140.
11. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, Ciceri F, COVID-19 BioB Outpatient Clinic Study group, Rovere-Querini P, Benedetti F. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain Behav Immun* 2021; 94: 138–147.

12. Taylor RR, Trivedi B, Patel N, Singh R, Ricketts WM, Elliott K, Yarwood M, White V, Hylton H, Allen R, Thomas G, Kapil V, McGuckin R, Pfeffer PE. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. *Clin Med (Lond)* 2021; : clinmed.2021-0037.
13. Todt BC, Szlejf C, Duim E, Linhares AOM, Kogiso D, Varela G, Campos BA, Baghelli Fonseca CM, Polesso LE, Bordon INS, Cabral BT, Amorim VLP, Piza FMT, Degani-Costa LH. Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. *Respir Med* 2021; 184: 106453.
14. Fortini A, Torrigiani A, Sbaragli S, Lo Forte A, Crociani A, Cecchini P, Innocenti Bruni G, Faraone A. COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge. *Infection* 2021; .
15. van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, van Hees HWH, van Helvoort H, van den Boogaard M, van der Hoeven H, Reijers MH, Prokop M, Vercoulen J, van den Heuvel M. Comprehensive health assessment three months after recovery from acute COVID-19. *Clin Infect Dis* 2020; : ciaa1750.
16. Wang PR, Oyem PC, Viguera AC. Prevalence of psychiatric morbidity following discharge after COVID-19 hospitalization. *Gen Hosp Psychiatry* 2021; 69: 131–132.
17. Careno L, Protti A, Dalla Corte F, Aceto R, Iapichino G, Milani A, Santini A, Chiurazzi C, Ferrari M, Heffler E, Angelini C, Aghemo A, Ciccarelli M, Chiti A, Iwashyna TJ, Herridge MS, Cecconi M, Humanitas COVID-19 Task Force. Short-term health-related quality of life, physical function and psychological consequences of severe COVID-19. *Ann Intensive Care* 2021; 11: 91.
18. Hall J, Myall K, Lam JL, Mason T, Mukherjee B, West A, Dewar A. Identifying patients at risk of post-discharge complications related to COVID-19 infection. *Thorax* 2021; 76: 408–411.
19. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, Okell T, Sheerin F, Xie C, Mahmud M, Mózes FE, Lewandowski AJ, Ohuma EO, Holdsworth D, Lamlum H, Woodman MJ, Krasopoulos C, Mills R, McConnell FAK, Wang C, Arthofer C, Lange FJ, Andersson J, Jenkinson M, Antoniadou C, Channon KM, Shanmuganathan M, Ferreira VM, Piechnik SK, Klenerman P, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine* 2021; 31: 100683.
20. Schandl A, Hedman A, Lyngå P, Fathi Tachinabad S, Svefors J, Roël M, Geborek A, Andersson Franko M, Söderberg M, Joelsson-Alm E, Darlington P. Long-term consequences in critically ill COVID-19 patients: A prospective cohort study. *Acta Anaesthesiol Scand* 2021; .
21. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; 397: 220–232.
22. Mandal S, Barnett J, Brill SE, Brown JS, Denny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR, ARC Study Group. “Long-COVID”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax* 2021; 76: 396–398.

23. Naidu SB, Shah AJ, Saigal A, Smith C, Brill SE, Goldring J, Hurst JR, Jarvis H, Lipman M, Mandal S. The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. *Eur Respir J* 2021; 57: 2004364.
24. Halpin SJ, Mclvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O’Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol* 2021; 93: 1013–1022.
25. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppego P, Avanzi GC, Baldon G, Bartolomei G, Battaglia M, Battistini S, Binda V, Borg M, Cantaluppi V, Castello LM, Clivati E, Cisari C, Costanzo M, Croce A, Cuneo D, De Benedittis C, De Vecchi S, Feggi A, Gai M, Gambaro E, Gattoni E, Gramaglia C, Grisafi L, Guerriero C, Hayden E, Jona A, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA Netw Open* 2021; 4: e2036142.
26. Yuan Y, Liu Z-H, Zhao Y-J, Zhang Q, Zhang L, Cheung T, Jackson T, Jiang G-Q, Xiang Y-T. Prevalence of Post-traumatic Stress Symptoms and Its Associations With Quality of Life, Demographic and Clinical Characteristics in COVID-19 Survivors During the Post-COVID-19 Era. *Front Psychiatry* 2021; 12: 665507.